COIOSDeep risk insights through multi-disciplinary research across the globe
red and black boat on water
Item refines Preprint · not peer-reviewed Added

Germline genomic risk score adds to PSA in predicting prostate cancer outcomes

In 428,512 Million Veteran Program men, a genetic risk score predicted prostate cancer treatment, metastasis and biopsy findings beyond PSA.

This preprint asked whether inherited genetic risk adds to prostate-specific antigen (PSA) for prostate cancer early detection. The P-CARE score, combining 601 variants, family history and ancestry, was tested in 428,512 Million Veteran Program men. High versus low P-CARE risk gave a hazard ratio of 3.32 for both treatment and metastasis. Men aged 40-49 with PSA 1-3 ng/mL had 15-year treatment or metastasis risks of 2.6%, 4.5% and 10.2% by group. It also predicted clinically significant cancer on biopsy (odds ratio 2.96), and results held in the Prostate Cancer Prevention Trial. The study is observational and the score has not been tested in a prospective screening programme.

Why it is interesting: In men aged 40-49 with PSA 1-3 ng/mL, 15-year treatment or metastasis probability was 10.2% at high P-CARE risk. It was 2.6% at low risk, and findings held in a separate trial.

Source
medRxiv, 19 November 2026
DOI
10.64898/2026.11.17.26368323
Type
Preprint
Design
Cohort study of germline polygenic hazard score plus PSA, 428,512 men in the Million Veteran Program with external validation in the Prostate Cancer Prevention Trial; 15-year outcomes
Verdict
Refines prior evidence
Driver
Cancer
Driver
What linked data reveals

Other drivers in Health today